Mounjaro vs Wegovy

Mounjaro (tirzepatide) and Wegovy (semaglutide) are frequently compared, but it is important to understand that they are FDA-approved for different primary indications. According to FDA prescribing information, Mounjaro is approved for type 2 diabetes management, while Wegovy is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and for cardiovascular risk reduction. This is a cross-indication comparison -- these medications are not interchangeable from a regulatory or insurance standpoint.

The two drugs also differ in their mechanism of action. Mounjaro is a dual GIP/GLP-1 receptor agonist, meaning it activates receptors for both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Wegovy is a GLP-1 receptor agonist only. In clinical trials, both showed meaningful weight reduction. In the SURMOUNT-1 trial, participants on the highest dose of tirzepatide achieved approximately 22.5% mean body weight loss over 72 weeks. In the STEP 1 trial, semaglutide 2.4 mg produced approximately 16.9% mean weight loss over 68 weeks. These were separate trials with different populations and study designs, so cross-trial comparisons have significant limitations.

Patients researching these medications should be aware that a physician's choice between them depends on multiple clinical factors, including whether the patient has a type 2 diabetes diagnosis, their cardiovascular risk profile, insurance formulary coverage, and individual response to treatment. Talk to your doctor about which medication and indication is most appropriate for your health goals.